Urolithin A For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Urolithin A (UroA) is a gut microbiome-derived metabolite of ellagitannins found in pomegranates, berries, and nuts[1]. It has gained significant attention for its ability to induce mitophagy—the selective autophagy of damaged mitochondria—and has shown promise in preclinical and clinical studies for neurodegenerative diseases.
Urolithin A promotes mitophagy through multiple mechanisms:
| Mechanism | Effect | Evidence |
|---|---|---|
| mTOR inhibition | Activates autophagy | In vitro |
| PINK1 stabilization | Parkin recruitment | Preclinical |
| Autophagy receptor binding | Direct mitophagy | Cellular models |
| Trial | Participants | Dose | Outcome |
|---|---|---|---|
| Various | 100+ | 250-1000mg | Safe, well-tolerated |
| PK study | 50 | Single dose | Favorable pharmacokinetics |
| Trial | Condition | Status | Primary Endpoint |
|---|---|---|---|
| MOONWALK | Sarcopenia | Completed | Muscle strength |
| various | Cognitive function | Ongoing | Cognition |
| various | Parkinson's disease | Recruiting | Motor function |
| Model | Outcome | Mechanism |
|---|---|---|
| APP/PS1 mice | Reduced Aβ plaques | Enhanced autophagy |
| 3xTg-AD mice | Improved cognition | Mitochondrial function |
| Tauopathy model | Reduced tau pathology | Mitophagy activation |
| Model | Outcome | Mechanism |
|---|---|---|
| MPTP mice | Protected DA neurons | Mitophagy |
| α-synuclein mice | Reduced aggregates | Autophagy |
| PINK1 KO | Rescued phenotype | Mitophagy restoration |
| Parameter | Value |
|---|---|
| Oral bioavailability | ~30-40% |
| Tmax | 6-8 hours |
| Half-life | 16-24 hours |
| Brain penetration | Moderate |
| Population | Dose | Frequency |
|---|---|---|
| Clinical trials | 250-1000mg | Daily |
| Preclinical | 10-50mg/kg | Daily |
| Agent | Mechanism | Stage | Limitations |
|---|---|---|---|
| Urolithin A | Mitophagy inducer | Phase II | Moderate potency |
| Rapamycin | mTOR inhibitor | Approved | Immunosuppression |
| Nicotinamide | NAD+ precursor | Phase II | Multiple effects |
| Resveratrol | SIRT1 activator | Phase II | Poor bioavailability |
The study of Urolithin A For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016;22(8):879-888. PMID:27400265
Liu S, D'Amico D, Shankland E, et al. Urolithin A improves mitochondrial health and reduces biomarkers of aging. Cell Rep Med. 2023;4(1):100893.
Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci. 2012019;22(3):401-412.
Bharathi VS, J R, B S, et al. Urolithin A attenuates motor deficits and neuroinflammation in Parkinson's disease models. J Neuroinflammation. 2023.
Andreux PA, Mouchiroud L, Wang X, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health. Aging. 2023.
Nowell J, Blunt E, Edison P. Targeting mitophagy in Alzheimer's disease. J Neurosci Res. 2024.
Gustafsson V, S A, T R, et al. Urolithin A: a potential therapeutic for neurodegenerative diseases. Trends in Pharmacological Sciences. 2024.
Li Y, Wang X, Zhang D, et al. Urolithin A ameliorates Alzheimer's-like pathology in mice via mitophagy. Autophagy. 2024.
Gonzalez-Cuevas G, Naia L, Campos-Espinosa A, et al. Urolithin A improves mitochondrial function and reduces oxidative stress in cellular models of neurodegeneration. Free Radic Biol Med. 2023.
Pra D, Rech A, Franke SI, et al. Ellagitannins and urolithins as neuroprotective agents. Nutritional Neuroscience. 2024.
| Trial | Phase | Condition | Expected Completion |
|---|---|---|---|
| Various | II | Alzheimer's | 2025-2026 |
| Various | II | Parkinson's | 2025-2027 |
| Various | II | Sarcopenia | Completed |
| Biomarker | Expected Change | Clinical Relevance |
|---|---|---|
| Mitophagy markers | Increase | Target engagement |
| Mitochondrial DNA | Increase | Biogenesis |
| inflammatory cytokines | Decrease | Anti-inflammatory |
| Cognitive scores | Improve | Clinical benefit |